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ABSTRACT  Liquid  medium  cultures  of three  human  cell  lines (B-lymphoma,  myeloma,  and 
squamous lung carcinoma) with population-doubling times (PDT) and cloning efficiencies (CE) 
in the range of 32-43 h and 0.01-5.6%, respectively, were exposed to 5-azacytidine (5-azaC) 
for 3 d. The doses used (1-3/zM) were found to be nontoxic  as measured by cell growth in 
liquid  and  semisolid agar medium  and  to  be  nonmutagenic  as  measured by  the  rate of 
generation  of ouabain-  and 6-thioguanine-resistant  cell variants. After 5-azaC treatment,  cell 
samples were subsequently  harvested every day and assayed for their CE in semisolid agar 
medium.  For each cell line, 30 to 42 individual  clones were harvested at the day of maximal 
CE and expanded  in liquid culture medium.  PDT and CE were determined  for each subclone 
about  every  6  wk for  12  too.  The  majority  of the  subclones had  unaltered  PDT and  CE 
compared to the original lines. However, several clones had profoundly changed proliferative 
activity with PDT on ~12-14 h and/or CE 5 to >50%. Some of the clones with altered growth 
properties  reverted  to PDT and/or CE values of untreated  clones. However,  a few clones of 
each line had stable alterations with PDT on 12-14 h and CE 5 to >50%; these clones were 
all significantly hypomethylated.  It is concluded  that the human gene repertoire  does contain 
genes that appropriately  activated  can  result in growth properties  with very short  PDT and 
high CE (and comparable  to animal cell lines), and that this activation  may be obtained  by 5- 
azaC treatment.  It is conceivable that the procedure  here described to alter growth properties 
of human cell lines may be applied to experimental situations, where alterations of cell growth 
properties are desired. 
Many reports in recent years on regulation of both cellular 
0-6)  and  viral~ genes  (7-11)  have  provided  experimental 
support  to  the  hypothesis  (12-15)  that  5-methylcytosine 
(mSCyt) t may be important in the regulation of gene expres- 
sion. Moreover, a  number of experiments have shown that 
exposure  of cells  to  5-azacytidine  (5-azaC)  may  result  in 
hypomethylation of DNA and cause expression of otherwise 
silent genes of both cellular and viral origin (for review, cf. 
references  16,  17)  to  the  extent  that  it  mimics  mutation 
induced genetic alterations, e.g., reversion frequency of thy- 
Abbreviations used in this paper."  5-azaC,  5-azacytidine; CE, clon- 
ing efficiency;  mSCyt, 5-methylcytosine;  Oua  r, ouabin resistant; PDT, 
population-doubling time; RPMI/FCS, RPMI-1640 medium SUlSple- 
merited with 0.3% L-glutamine and  10-15% fetal calf serum; 6-TG  ~, 
6-thioguanine resistant. 
midine kinase negative cells to thymidine kinase positive cells 
(18). 
The growth properties of malignant tumor cell lines are at 
least in part reflected in the growth rate and CE. However, it 
has hitherto not been possible by exogenous factors to alter 
profoundly these  biological  features,  despite  numerous  at- 
tempts that  mainly have been  based  on  alterations  in  the 
growth medium conditions such as addition of growth factors 
like  insulin  and  transferrin.  Moreover,  human  tumor  cell 
lines generally have population-doubling times (PDT) >20- 
24  h  and  lower cloning efficiencies (CE)  than  comparable 
animal lines, and it has been an unresolved question, whether 
the gene repertoire in human cells upon appropriate activation 
can result in growth properties comparable to rodent cells. 
Finally, it is for many purposes desirable to have cell lines 
with high proliferative activity. 
THE IOURNAL OF  CELL BIOLOGY • VOLUME 100 FEBRUARY 1985 508-513 
508  © The Rockefeller University Press  • 0021-9525/85/02[508106  $1.00 We  report  here  that  treatment  with  5-azaC  resulted  in 
profound  changes of growth  rates  and  CE  of three  human 
tumor  cell lines (lymphoma,  myeloma,  squamous  cell lung 
carcinoma). In particular, cell lines with very short PDT  (12- 
14 h) and/or  high CE (5  to >50%)  values were obtained and 
were found to b¢ significantly hypomethylated. This indicates 
that  mSCyt  is  a  significant  regulatory  factor  in  relation  to 
genes that are involved in the determination of PDT  and CE. 
Our experiments  also suggest a  general method  to alter pro- 
foundly the growth properties of human  cells. 
MATERIALS  AND  METHODS 
Cell Lines and Treatment with 5-azaC:  The three human cell 
lines,  RH-L4 (B-lymphoma [19]), RH-SLC-LI l  (squamous lung carcinoma 
line [20]), and SKO-007 (myeloma [21]) were maintained routinely in RPMI- 
1640 medium supplemented with 0.3%  L-glutamine  and  10-15%  fetal calf 
serum (RPMI/FCS). 5-AzaC was added to the culture medium, and the cells 
grown in this medium for 3 d. Subsequently,  cells were harvested  each day 
from the liquid cultures and cloned in semisolid agar medium (Bacto-Agar, 
Difco Laboratories,  Inc., Detroit, MI) in RPMI/FCS. The procedure is outlined 
in Fig. 1. 
Assays for Toxicity and Mutagenicity of 5-AzaC:  The dose of 
5-azaC was for each cell line chosen as the highest concentration that did not 
show any sign of  toxic or mutagenic effects on the cells. Toxicity was measured 
by the effect on growth properties as estimated from conventional growth 
curves and from CE in semisolid agar medium. In the latter test, l03 cells were 
seeded into wells of 24-weU plates (Nunc, Roskilde, Denmark) in 1.0 ml 0.3% 
agar-RPMI/FCS semisolid  medium. The number of clones (>50 cells) was 
counted under a  microscope 2-3 wk later and the CE determined as the 
percentage of clones among the total number of cells seeded. The experiments 
demonstrated (Fig. 2) that a dose of 3 #M 5-azaC was applicable  for the RH- 
L4 and the RH-SLC-L11 line, and a dose of 1.0 #M for the SK0-007 cell line. 
The mutagenic effect of 5-azaC was analyzed by measurement of  the rate of 
induction of ouabain-resistant (Oua') variants and of 6-thioguanine-resistant 
(6-TO') variants.  Cells were grown for 3 d in 5-azaC in large cultures,  washed 
three times in RPMI-1640  medium and reseeded into wells of  24-well plates in 
1.0 ml RPMI/FCS with l0 ,M ouabain with a cell concentration of 5 x  106/ 
well, 10~/well, 5 x  10~/weli, or 5 x  104/well. 24 wells were seeded for each cell 
concentration and medium exchanged every 2-3 d. In wells with cell growth, 
the ouabain concentration was increased to 100 ,M, and the number of wells 
with growth counted 2 wk later. The mutation frequency was calculated  from 
the number of wells with growth in the cell concentration that did not result in 
growth in all  wells; e.g., growth in all wells seeded with  l06 cells indicates 
mutation frequency >10  ~, and growth in 5 wells of 24 wells seeded with l05 
cells/well indicates a mutation frequency at ~2 x  l0  ~. Table ! shows that the 
doses selected for the three lines (3 ,M for RH-L4 and RH-SCL-L1 l, l ,M for 
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FIGURE  1 
Cultivation in conventional  medium 
( RPM1-1640  + 10 O/o  FCS) 
Experimental  procedure  for  5-azaC  treatment  of  the 
human  B-lymphoma cell  line (RH-L4), the human SKO-O07  mye- 
Ioma cell line, and the human squamous lung carcinoma cell line 
(RH-SLC-L11). 5-AzaC (3 ~M for  RH-L4;  1 /.tM for SKO-007;  3 #M 
for  RH-SLC-L11)  was added to the culture  medium at day 0  and 
removed 3 d later. The cells were then grown in RPMI-1640 medium 
with 15% FCS and without 5-azaC. Cells were harvested each day 
from the liquid cultures and cloned in 0.3% semisolid agar medium 
(Bacto-agar, Difco Laboratories, Inc.)in  RPMI-1640 with  15% FCS. 
Clones  were  scored  14-30  d  later.  5-AzaC-treated  RH-SLC-L11 
were cloned every day for 30 d  and the RH-L4 and SKO-007 cell 
lines for 16-28 d. 
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FIGURE  2  Growth  curves  and  cloning  efficiency  of  RH-L4,  RH- 
SLC-L11, and SKO-O07 cells after treatment with 5-azaC in various 
doses (×, no treatment; O,  1.0 pM; A, 3.0 pM; O, 6.0 pM; &,  10.0 
#M). The cloning efficiencies are indicated in parenthesis. The 5- 
azaC treatment was for all doses done for 3 d as described in detail 
in Materials and Methods. 
TABLE  I 
Data 
No.  of drug resistant 
cells/106 cells 
I0 #M  I  pM 6- 
Cell line  Treatment*  Oua  TG 
RH-L4  None  0.2  0.3 
0.1  pM 5-azaC  0.1  0.5 
1.0 ,M  5-azaC  0.2  0.5 
3.0 #M 5-azaC  0.2  0.5 
6.0 ,M  5-azaC  0.2  0.3 
3.0 ,g/ml MNNG  19  12 
RH-SLC-L11  None  0.1  0.2 
0.1  pM 5-azaC  0.1  0.1 
1.0 pM 5-azaC  0.1  0.1 
3.0 pM 5-azaC  0.1  0.1 
6.0 #M 5-azaC  0.2  0.3 
3.0/zg/ml MNNG  11  9 
SKO-O07  None  0.7  1.0 
0.1 pM 5-azaC  0.5  1.0 
1.0 #M 5-azaC  0.7  1.0 
3.0 pM 5-azaC  0.7  1.0 
6.0 pM 5-azaC  1.0  1.7 
3.0 pg/ml MNNG  9  14 
Frequency of Oua' and 6-TG  ' cells in 3 human cell lines after treatment 
with 5-azacytidine  (5-azaC) or with N-methyI-N'-nitro-N-nitrosoguanidine 
(MNNG). 
* The cells were treated for 3 d with 5-azaC, washed, and reseeded in wells 
(as indicated in Materials and Methods) with either Oua or 6-TG. Treatment 
with MNNG was performed as described by Boon and Kellerman (22). The 
cells were exposed to MNNG at 3 pg/ml for 60 min, washed, and placed in 
culture. 
SKO-007) did not result in a measurable  increase in the number of Qua' or 6- 
TG' variants. 
DNA-Methylation:  The amounts of mSCyt in newly replicated DNA 
was estimated by labeling the cells with ]'C-deoxycytidine  (120 nCi/ml; sp.act, 
460  Ci/mol; Amersham) and  subsequently  hydrolysis  of the bases in 96% 
formic acid for 60 rain at  175°C, separation  of the bases by thin-layer chro- 
matography (23), and the percentage of enzymatic methylation calculated  as 
100% mSCyt(cpm)/Cyt(cpm)  + mSCyt(cpm). 
RESULTS 
Effects of 5-AzaC on CE 
The  CE  of RH-L4  cells  varied  significantly  after  5-azaC 
treatment  (Fig.  3),  and  was  associated  with  a  remarkable 
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corresponding data  for  the  effects  of 5-azaC  on  a  human 
myeloma line and a  squamous cell lung carcinoma line are 
seen in Table lI. 
30-42 clones were harvested individually from agar cultures 
of the untreated parental cell lines and 10-20 clones from 5- 
azaC-treated cultures. All clones were subsequently expanded 
in liquid culture medium. The cloning efficiency and growth 
rate were determined for each clone (Table III) after expansion 
to ~  106-3  X  106 cells. A high growth rate was not necessarily 
associated with high CE  and vice versa.  The values for CE 
and growth rate of the clones harvested from untreated cul- 
tures  did  not  vary  significantly.  Expression  of cell  surface 
HLA class I and class II antigens was not changed significantly 
either quantitatively or qualitatively in the various clones as 
analyzed on a fluorescence activated cell sorter after staining 
with fluorescein isothiocyanate-conjugated monoclonal an- 
tibodies against monomorphic determinants of HLA class I 
and class II antigens (data not shown). 
CE and Growth Rate of 5-AzaC- 
treated Subclones 
Clones with  high  and  low  CE  and/or growth  rates were 
selected from the RH-L4 line for further analyses and main- 
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FIGURE  3  Cloning  efficiency  of  the  human  RH-L4  B-lymphoma 
cell line 0-16 d after the cells had been cultivated for 3 d  in RPMI- 
1640 medium with  15% FCS, 0.3% L-glutamine, and 3 pM 5-azaC. 
The cells were cloned in 0.3% agar in  24-well  plates (Nunc,  Ros- 
kilde,  Denmark)  with  103-5  x  104 cells  per well.  The number of 
clones were counted 14-24 d later and cloning efficiency calculated 
as the number of colonies per 100 cells seeded. Control  cultures 
were RH-L4 cells in RPMI-1640 medium with  15% FCS, and were 
continuously adjusted to the same density as 5-azaC-treated cells. 
The  experiments  were  repeated  five  times.  The  curve  shows  a 
typical result.  Colonies were harvested  individually from  the agar 
cultures at day 5 and each colony expanded in liquid  RPMI-1640 
medium with  15% FCS. 
FIGURE  4  Typical RH-L4 B-lymphoma cell colony in semisolid agar 
medium  14 d  after seeding of cells taken from  (top) conventional 
cultures and  (bottom) cultures  treated  for  3  d  with  3  pM  5-azaC 
and subsequently cloned. 
TABLE  II 
Effects of S-Azacytidine on CE of Three Human Tumor Cell Lines 
Cell lines 
RH-L4  SKO-O07  RH-SLC-L11 
PDT before 5-azaC*  35 h 
CE before 5-azaC  ~  0.04 +  0.01% 
Maximum CE after 5-azaC treatment  3.7 ±  0.3% 
Day of maximum CE after removal of 5-azaC from  5 
culture medium 
43 h 
0.01  ±  0.01% 
2.2 ±  0.3% 
17 
32 h 
5.6 +  0.4% 
12.8 +  1.2% 
12 
* PDT and CE were established as described in Materials and Methods. 
* The values are mean ± SD of three to eight experiments. The variation in PDT was below 15% for all three cell lines. 
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PDT and CE of Subclones of the RH-L4, SKO-O07, and RH-SLC-L I I Cell Lines after Treatment with 5-AzaC 
Cell line 
PDT in hours 25-35 d 
5-AzaC treat-  after harvest of colonies* 
Subclone*  No.  ment  (range) 
CE 28-31  d  after harvest of colo- 
nies  ~ (range) 
RH-L4 
SKO-O07 
RH-SCL-L11 
% 
40-71  -  34 (29-41)  0.04 (0.02-0.06) 
1  +  14  24.4 
3  +  26  >50 
13  +  12  7.0 
14  +  14  9.0 
17  +  18  5.6 
18  +  31  12.6 
2, 5, 6, 7, 8, 9,  10, 11,  +  32-41  0.01-0.08 
12,  15,  16,  19, 20 
20-50  -  43 (37-54)  0.01% (<0.01-0.0) 
5  +  18  1.6 
6  +  44  16.5 
8  +  15  11.3 
1, 2, 3, 4, 7, 9,  10  +  42-49  <0.01 
25-67  -  32 (24-36)  5.5% (3.7-7.1) 
2  +  34  >50 
3  +  14  11.0 
6  +  16  5.8 
9  +  41  6.1 
11  +  24  21.8 
1, 4, 5, 7, 8,  10,  11  +  30-41  5.1-6.2 
* Colonies were harvested individually from the agar under a microscope and expanded in liquid RPMI-1640 medium with 10-15% FCS. 
* Population doubling time and cloning efficiency were determined as described in Materials and Methods. Moreover, flow cytofluometric measurements {data 
not shown) on propidium  iodine stained nuclei  revealed that the shortening of PDT in all cases was a result of a decrease in G1-phase duration and an 
increase in growth fraction. 
mined in conventional RPMI-1640 medium with  10% FCS. 
The CE and generation doubling times were determined every 
6  wk  for a  12-rap period  (Table  IV).  Most  of the  clones 
reverted to values of untreated cultures, but some clones have 
been stable in respect to their CE and growth rates now for 
more than  12 mo. The total amount of DNA in the clones 
did not differ significantly from the original cell lines.  How- 
ever, 5-azaC treatment resulted in significant hypomethyla- 
don of most of the subclones, whereas the level of mSCyt in 
untreated  subelones was  stable  (Table  V).  Those  5-azaC- 
treated clones that reverted to growth properties of untreated 
clones regained all approximately the same amounts of mSCyt 
as untreated cultures (data not shown). 
DISCUSSION 
The data demonstrate that the growth rates and CEs of  human 
malignant cell  lines  can  be significantly altered  by 5-azaC 
treatment in doses that seemed neither mutagenic nor toxic 
as measured by the effects on cell growth and on the genera- 
tion ofOua  r and/or 6-TG' variants; this is in line with findings 
in other cell systems (24).  It seems also excluded that sub- 
clones  with  short  PDT  and/or  high  CE  preexisted  in  the 
culture, because (a) such subelones within only a few weeks 
would be predominant in the culture, and the culture would 
consequently have a  very fast growth rate and/or high CE, 
and because (b) all subclones isolated from the  nontreated 
culture  had  growth  properties  comparable  to  the  original 
culture. 
The effects of 5-azaC can  therefore be assumed to be a 
result  of its incorporation  into  DNA  in  place  of cytosine, 
resulting in expression of genes that have been silent due to 
mSCyt or due to the general inhibitory effect of 5-azaC on 
DNA methylase activity (16).  This concurs with the hypo- 
methylated state of most clones treated with 5-azaC, although 
hypomethylation patterns are only very indirect evidence of 
the importance of methylation in gene control, as the replace- 
ment of cytosine by 5-azaC during DNA replication can be 
assumed to be a random process. Moreover, it is possible that 
the  gene(s)  responsible  for  the  altered  growth  rate/CE  is 
different not only between the three histologically different 
types  of malignant  cell  lines,  but  also  in  relation  to  the 
different subelones of a given cell line. However, this problem 
cannot be approached properly before the genes controlling 
growth  activity and  clonogenicity are  known.  The  present 
experiments nevertheless strongly indicate that the genome of 
human malignant cells contains genes that appropriately ac- 
tivated result in profound alterations of proliferation patterns 
that may result in cell lines with very short PDT and/or high 
CE. 
Intratumoral phenotypic diversity is known to be expressed 
in  malignant  cell  populations  in  respect  to  a  number  of 
biological features, including growth rate and clonability (25- 
30) and onc-gene expression (31). The biological basis for this 
diversity is unknown, but involves probably both genetic and 
epigenetic factors. The effects of 5-azaC on the proliferative 
features of the three lines suggest that changes in methylation 
patterns have a  central  role in the generation  of biological 
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Data 
Time after harvest of tumor cell colonies from agar 
d 
60-65  104-114  172-186  200-365 
Cell line  Subclone No.  PDT  CE  PDT  CE  PDT  CE  PDT  CE 
RH-L4 
SKO-007 
RH-SCL-L11 
h  %  h  %  h  %  h  % 
1  35  0.08  32  0.05  39  0.06  37  0.05 
3  32  >50  30  >50  31  >50  32  >50 
4  14  0.4  14  8.3  12  7.6  12  8.3 
13  14  1.1  16  1.0  18  0.7  18  0.1 
14  14  9.0  12  9.0  11  8.5  14  9.0 
17  37  3.4  37  1.8  38  1.0  34  1.0 
18  34  2.2  36  0.9  33  0.06  33  0.05 
5  43  <0.01  47  <0.01  48  <0.01  44  <0.01 
6  51  2.6  49  2.3  55  0.1  51  0.1 
8  16  10.2  45  9.9  47  7.6  47  8.6 
2  36  9.6  42  7.2  36  6.1  35  5.8 
3  16  4.9  17  5.9  28  5.7  30  5.7 
6  12  6.8  13  7.2  15  8.1  16  7.2 
9  44  5.7  49  6.1  44  7.2  46  5.8 
11  49  19.3  48  18.7  47  16.2  43  17.3 
Changes in PDT and CE in subclones of RH-L4, sKO-007, and RH-SCL-L11 as a function of time after treatment with 5-azaC.  All subclones were maintained in 
liquid RPMI-1640 medium with  10-15% FCS. The experiment has been run thrice and the results in the table are from the second experiment. PDT and CE 
were determined as explained in Materials and Methods. 
TABLE V 
DNA Methylation  in 5ubclones of RH-L4, SKO-O07, and RH- 
SCL-L11 with Stable (>12 too) Changes in PDT and CE 
%  mSCyt of 
5-AzaC  total cyto- 
Cell line  Subclone No.  treatment  sine 
RH-L4 
SKO-O07 
RH-SCL-L11 
Original 
,  RH-L4 clone  -  3.9 4- 0.3 
31  subclones  -  3.7 4- 0.5 
3  +  0.7 +  O.2 
4  +  2.4+0.1 
13  +  0.4 +  0.3 
14  +  0.5 4- 0.3 
Original 
SKO-007 clone  -  4.6 ___ 0.2 
30 subclones  -  4.7 4- 0.5 
6  +  2.1  _  0.1 
8  +  0.7 _  0.3 
Original 
RH-SCL-L11  clone  -  3.0 -  0.1 
42 subclones  -  3.0 _  0.4 
2  +  2.1  +  0.1 
6  +  O.8 +  0.2 
11  +  1.74-0.1 
diversity. Such diversity may on the other hand be a necessary 
feature of malignant behavior (26, 32) as well as it is conceiv- 
able that demethylation is an important event in oncogenesis 
(33). It was also recently demonstrated that demethylation of 
certain genes in the  murine  Lewis lung tumor system may 
lead  to  metastatic  activity of otherwise  nonmetastatic  cells 
(34). 
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Finally, the various subclones here reported may provide 
the experimental basis for isolation of DNA sequences that 
can be useful for analysis of the genetic basis for alteration of 
growth rate  and  cloning efficiency, e.g.,  through studies  of 
certain "candidate" genes like various oncogenes and genes 
encoding for various growth factors. 
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